title: Phase I study of oral doxifluridine using two schedules.
authors.affiliation: Division of Oncology, University Hospital, Geneva, Switzerland.
authors.forename: P
authors.initials: P
authors.lastname: Alberto
authors.forename: J J
authors.initials: JJ
authors.lastname: Winkelmann
authors.forename: N
authors.initials: N
authors.lastname: Paschoud
authors.forename: R
authors.initials: R
authors.lastname: Peytremann
authors.forename: A
authors.initials: A
authors.lastname: Bruyere
authors.forename: A
authors.initials: A
authors.lastname: Righetti
authors.forename: G
authors.initials: G
authors.lastname: Decoster
authors.forename: E E
authors.initials: EE
authors.lastname: Holdener
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000633:toxicity; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage* / Q000633:toxicity; D006801:Humans; D007536:Isomerism; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D005467:Floxuridine; C025034:doxifluridine